

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI168143

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056304/0581)
CONVEYING PARTY DATA	
Name	Execution Date
The Bank of New York Mellon	04/11/2024
RECEIVING PARTY DATA	
Company Name:	Bausch + Lomb Ireland Limited
Street Address:	3013 Lake Drive
Internal Address:	Citywest Business Campus
City:	Dublin 24
State/Country:	IRELAND
Postal Code:	D24PPT3
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17022398
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8004945225
Email:	ipteam@cogencyglobal.com
Correspondent Name:	Stewart Walsh
Address Line 1:	1025 Connecticut Ave NW, Suite 712
Address Line 2:	Cogency Global Inc.
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20036
ATTORNEY DOCKET NUMBER:	2331149 PAT BNYM 14
NAME OF SUBMITTER:	Andrew Hackett
SIGNATURE:	Andrew Hackett
DATE SIGNED:	04/17/2024
Total Attachments: 9	
source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF 05630.40581#page1.tif	
source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF 05630.40581#page2.tif	

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page3.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page4.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page5.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page6.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page7.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page8.tif

source=FOR FILING 14. Corrective Release of Patent Security Interests (BNYM) (execution version) - RF
05630.40581#page9.tif

OMNIBUS PATENT SECURITY RELEASE AGREEMENT

This **OMNIBUS PATENT SECURITY RELEASE AGREEMENT** (the "Release") is made as of April 11, 2024 by **THE BANK OF NEW YORK MELLON**, as notes collateral agent for the Noteholder Secured Parties (as defined in the Security Agreement referred to below) (in such capacity, the "Collateral Agent").

W I T N E S S E T H

WHEREAS, pursuant to (i) that certain U.S. Pledge and Security Agreement dated as of March 21, 2017 (as amended or otherwise modified, the "March 2017 Security Agreement"), (ii) that certain U.S. Pledge and Security Agreement dated as of October 17, 2017 (as amended or otherwise modified, the "October Security Agreement"), (iii) that certain U.S. Pledge and Security Agreement dated as of March 8, 2019 (as amended or otherwise modified, the "March 2019 Security Agreement"), (iv) that certain U.S. Pledge and Security Agreement, dated as of June 8, 2021 (as amended or otherwise modified, the "June 2021 Security Agreement"), (v) that certain U.S. Pledge and Security Agreement, dated as of February 10, 2022 (as amended or otherwise modified, the "February 2022 Security Agreement"), and, together with the March 2017 Security Agreement, the October Security Agreement, the June 2021 Security Agreement, the February 2022 Security Agreement, and the June 2021 Security Agreement, the "Security Agreements"), (vi) that certain Patent Security Agreement, dated February 13, 2018, by and among the grantors parties thereto and the Collateral Agent (the "February 2018 Patent Security Agreement"), (vii) that certain Intellectual Property Security Agreement, dated March 8, 2019, by and among the grantors parties thereto and the Collateral Agent (the "March 2019 Patent Security Agreement"), (viii) that certain Intellectual Property Security Agreement, dated July 1, 2019, by and among the grantors parties thereto and the Collateral Agent (the "July 2019 Patent Security Agreement"), (ix) that certain Intellectual Property Security Agreement, dated May 20, 2021, by and among the grantors parties thereto and the Collateral Agent (the "May 2021 Patent Security Agreement"), (x) that certain Intellectual Property Security Agreement, dated August 25, 2021, by and among the grantors parties thereto and the Collateral Agent (the "August 2021 Patent Security Agreement"), (xi) that certain Patent Security Agreement, dated October 4, 2021, by and among the grantors parties thereto and the Collateral Agent (the "October 2021 Patent Security Agreement"), (xii) that certain Intellectual Property Security Agreement, dated November 23, 2021, by and among the grantors parties thereto and the Collateral Agent (the "November 2021 Patent Security Agreement") and (xiii) that certain Patent Security Agreement, dated June 10, 2022, by and among the grantors parties thereto and the Collateral Agent (the "June 2022 Patent Security Agreement"), together with the February 2018 Patent Security Agreement, the March 2019 Patent Security Agreement, the July 2019 Patent Security Agreement, the May 2021 Patent Security Agreement, the August 2021 Patent Security Agreement, the October 2021 Patent Security Agreement, the November 2021 Patent Security Agreement, and the June 2022 Patent Security Agreement, the "IP Security Agreements"), pursuant to which Bausch & Lomb Incorporated, a New York corporation ("B&L"), Bausch + Lomb Corporation, a corporation incorporated under the *Canada Business Corporations Act* ("B+L") and Bausch + Lomb Ireland Limited, a company incorporated in Ireland having company registration number 677764 and having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24 ("Ireland Limited") and, together with B&L and B+L, (the "Grantors", each a "Grantor"), granted the Collateral Agent a continuing security interest in all of such Grantors' right, title and interest in, to and under the patent collateral of the Grantors identified on Schedule A attached hereto (the "IP Security Interest");

WHEREAS, the February 2018 Patent Security Agreement was recorded with the United States Patent and Trademark Office on February 26, 2018 at Reel 045444, Frame 0634;

WHEREAS, the March 2019 Patent Security Agreement was recorded with the United States Patent and Trademark Office on March 11, 2019 at Reel 048556, Frame 0758;

WHEREAS, the July 2019 Patent Security Agreement was recorded with the United States Patent and Trademark Office on July 3, 2019 at Reel 049672, Frame 0652;

WHEREAS, the May 2021 Patent Security Agreement was recorded with the United States Patent and Trademark Office on May 20, 2021 at Reel 056304, Frame 0581;

WHEREAS, the August 2021 Patent Security Agreement was recorded with the United States Patent and Trademark Office on August 25, 2021 at Reel 057287, Frame 0160;

WHEREAS, the October 2021 Patent Security Agreement was recorded with the United States Patent and Trademark Office on October 5, 2021 at Reel 057821, Frame 0800;

WHEREAS, the November 2021 Patent Security Agreement was recorded with the United States Patent and Trademark Office on November 24, 2021 at Reel 058205, Frame 0889; and

WHEREAS, the June 2022 Patent Security Agreement was recorded with the United States Patent and Trademark Office on June 13, 2022 at Reel 060346, Frame 0705

WHEREAS, pursuant to that certain Officers' Certificate dated April 11, 2024, Bausch Health Companies Inc. and Bausch Health Americas, Inc. have certified to the Collateral Agent that the release of the IP Security Interest is authorized and permitted by, and all conditions precedent relating to the release of the IP Security Interest have been complied with in respect of, the indentures and collateral documents including without limitation the IP Security Agreements;

WHEREAS, the Grantors have requested, and the Collateral Agent agrees to provide, a document suitable for recording in the USPTO for purposes of recording the release, relinquishment and discharge of its interest in the IP Security Interest; and

WHEREAS, the Collateral Agent, on behalf of itself and the Secured Parties, solely in reliance on the representations, warranties and certifications made pursuant to the aforementioned Officers' Certificate and an opinion of counsel dated the same date relating to the release of the IP Security Interest and without independent investigation, agrees to terminate and grant a release of the IP Security Interest as provided in this Release.


NOW THEREFORE, for good and valuable consideration previously tendered by the Grantors, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent, on behalf of itself and the Secured Parties, does hereby agree as follows:

1. All capitalized terms used but not otherwise defined herein have the meanings given to them in the IP Security Agreements.
2. The Collateral Agent, on behalf of itself and the Secured Parties, without representation, warranty or recourse, hereby (a) releases, relinquishes, terminates and discharges the IP Security Interest in its entirety and (b) reassigns to each Grantor any and all right, title and interest of any nature whatsoever which such Grantor may hold in or to the any of the patent collateral (including, without limitation, the Patents identified on Schedule A attached hereto) and associated common law rights and goodwill appurtenant thereto.
3. The Collateral Agent, on behalf of itself and the Secured Parties, acknowledges that the Grantors may record this Release with the United States Patent and Trademark Office and any other applicable governmental authority in their discretion.
4. At the request of the Grantors, the Collateral Agent, on behalf of itself and the Secured Parties, agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions necessary to carry out the purposes of this Release that are reasonably requested by the Grantors and at the cost and expense of the Grantors.
5. The Collateral Agent shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Release or for or in respect of the recitals contained herein.

[Signature page follows]

IN TESTIMONY WHEREOF, the Collateral Agent has executed this Release by its proper officers thereunto duly authorized.

THE BANK OF NEW YORK MELLON, as Collateral Agent

By: 
Name: Lisa Sollitto
Title: Vice President

Digitally signed by Lisa Sollitto
Date: 2024.04.09 10:22:56
+04'00'

[Signature Page to IP Release (Patents)]

PATENT
REEL: 067131 FRAME: 0633

Schedule A

See Attached

Patent Release Schedule

Reel/Frame: 045444/0634 - 2/13/2018 Security Interest - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
PHOTODYNAMIC THERAPY OF OCCULT AGE-RELATED MACULAR DEGENERATION	Feb 6, 2002	10/072272	Oct 11, 2011	8034803	Bausch + Lomb Ireland Limited
COMPOSITIONS AND METHODS FOR DELIVERY OF PHOTOSENSITIVE DRUGS	May 15, 2003	10/440505	Nov 25, 2008	7455858	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Mar 21, 2012	13/426470	Dec 15, 2015	9211214	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Oct 1, 2015	14/872248	Apr 24, 2018	9949877	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE	Nov 7, 2011	13/140411	Jan 5, 2016	9226917	Bausch + Lomb Ireland Limited
ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY A GINSENG EXTRACT	Feb 27, 2009	13/846267	Jun 9, 2015	9050313	Bausch + Lomb Corporation
SYNERGISTIC PHARMACEUTICAL COMPOSITION, METHOD OF MAKING SAME AND USE OF SAME	May 1, 2009	12/434289	Feb 4, 2014	8642094	Bausch + Lomb Corporation

Reel/Frame: 048556/0758 - 3/8/2019 Security Interest - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
CONTROLLED RELEASE MICROPARTICLES	Dec 1, 2006	11/607382	Nov 4, 2014	8877229	Bausch + Lomb Ireland Limited

Ocular Drug Delivery Devices	Jan 7, 2019	16/241558	Aug 22, 2023	11730697	Bausch + Lomb Ireland Limited
------------------------------	-------------	-----------	--------------	----------	-------------------------------

Reel/Frame: 049672/0652 - 7/1/2019 Intellectual Property Security Agreement - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
CONTROLLED RELEASE MICROPARTICLES	Dec 1, 2006	11/607382	Nov 4, 2014	8877229	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY OF OCCULT AGE-RELATED MACULAR DEGENERATION	Feb 6, 2002	10/072272	Oct 11, 2011	8034803	Bausch + Lomb Ireland Limited
COMPOSITIONS AND METHODS FOR DELIVERY OF PHOTSENSITIVE DRUGS	May 15, 2003	10/440505	Nov 25, 2008	7455858	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Mar 21, 2012	13/426470	Dec 15, 2015	9211214	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Oct 1, 2015	14/872248	Apr 24, 2018	9949877	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE	Nov 7, 2011	13/140411	Jan 5, 2016	9226917	Bausch + Lomb Ireland Limited
ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY A GINSENG EXTRACT	Feb 27, 2009	13/846267	Jun 9, 2015	9050313	Bausch + Lomb Corporation
SYNERGISTIC PHARMACEUTICAL COMPOSITION, METHOD OF MAKING SAME AND USE OF SAME	May 1, 2009	12/434289	Feb 4, 2014	8642094	Bausch + Lomb Corporation

Ocular Drug Delivery Devices	Jan 7, 2019	16/241558	Aug 22, 2023	11730697	Bausch + Lomb Ireland Limited
ACCOMMODATING 360 DEGREE SHARP EDGE OPTIC PLATE HAPTIC LENS	Jul 8, 2004	10/888163	Jun 30, 2009	7553327	Bausch + Lomb Ireland Limited
ACCOMMODATING 360 DEGREE SHARP EDGE OPTIC PLATE HAPTIC LENS	Jun 29, 2009	12/494190	Feb 7, 2012	8109998	Bausch + Lomb Ireland Limited
"W" ACCOMMODATING INTRAOCULAR LENS	Nov 14, 2007	11/940169	Jul 27, 2010	7763070	Bausch + Lomb Ireland Limited

Reel/Frame: 056304/0581 - 5/20/2021 Security Interest - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
GRAFTED POLYMER AND USE THEREOF	Sep 16, 2020	17/022398			Bausch + Lomb Ireland Limited

Reel/Frame: 057287/0160 - 8/25/2021 Security Interest - Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
ULTRASONIC NEEDLES AND TRANSDUCER ASSEMBLIES FORMED OF NON-METAL MATERIALS OR A COMBINATION OF MATERIALS	Jan 26, 2021	17/158562	Sep 12, 2023	11752035	Bausch + Lomb Ireland Limited

Reel/Frame: 057821/0800 - 10/4/2021 Security Interest - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
GRAFTED POLYMER AND USE THEREOF	Sep 16, 2020	17/022398			Bausch + Lomb Ireland Limited

CONTROLLED RELEASE MICROPARTICLE S	Dec 1, 2006	11/607382	Nov 4, 2014	8877229	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY OF OCCULT AGE- RELATED MACULAR DEGENERATION	Feb 6, 2002	10/072272	Oct 11, 2011	8034803	Bausch + Lomb Ireland Limited
COMPOSITIONS AND METHODS FOR DELIVERY OF PHOTOSENSITIV E DRUGS	May 15, 2003	10/440505	Nov 25, 2008	7455858	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Mar 21, 2012	13/426470	Dec 15, 2015	9211214	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY LASER	Oct 1, 2015	14/872248	Apr 24, 2018	9949877	Bausch + Lomb Ireland Limited
PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE	Nov 7, 2011	13/140411	Jan 5, 2016	9226917	Bausch + Lomb Ireland Limited
ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY A GINSENG EXTRACT	Feb 27, 2009	13/846267	Jun 9, 2015	9050313	Bausch + Lomb Corporation
SYNERGISTIC PHARMACEUTIC AL COMPOSITION, METHOD OF MAKING SAME AND USE OF SAME	May 1, 2009	12/434289	Feb 4, 2014	8642094	Bausch + Lomb Corporation
Ocular Drug Delivery Devices	Jan 7, 2019	16/241558	Aug 22, 2023	11730697	Bausch + Lomb Ireland Limited
ACCOMMODATI NG 360 DEGREE SHARP EDGE OPTIC PLATE HAPTIC LENS	Jul 8, 2004	10/888163	Jun 30, 2009	7553327	Bausch + Lomb Ireland Limited
ACCOMMODATI NG 360 DEGREE SHARP EDGE OPTIC PLATE HAPTIC LENS	Jun 29, 2009	12/494190	Feb 7, 2012	8109998	Bausch + Lomb Ireland Limited

"W" ACCOMMODATING INTRAOCULAR LENS	Nov 14, 2007	11/940169	Jul 27, 2010	7763070	Bausch + Lomb Ireland Limited
---	--------------	-----------	--------------	---------	----------------------------------

Reel/Frame: 058205/0889 - 11/23/2021 Security Interest – Bank of New York Mellon

Title	Filing Date	Application Number	Publication Date	Publication Number	Current Owner
Contact Lens Packaging	8/31/2021	17/462962	3/2/2023	{20230060534}	Bausch & Lomb Incorporated

Reel/Frame: 060346/0705 – 6/10/2022 Security Interest - The Bank of New York Mellon

Title	Filing Date	Application Number	Issue Date	Patent Number	Current Owner
ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY A GINSENG EXTRACT	Feb 27, 2009	13/846267	Jun 9, 2015	9050313	Bausch + Lomb Corporation
SYNERGISTIC PHARMACEUTICAL COMPOSITION, METHOD OF MAKING SAME AND USE OF SAME	May 1, 2009	12/434289	Feb 4, 2014	8642094	Bausch + Lomb Corporation